Graeme J. Moyle

Corporate Officer/Principal presso Chelsea & Westminster Hospital

60 anni

Health Technology

Consumer Services

Profilo

Graeme J.
Moyle is currently the Director-HIV Research Strategy at Chelsea & Westminster Hospital since 1994.
He previously worked as an Independent Director at Tobira Therapeutics, Inc. Dr. Moyle holds a doctorate degree from the University of Adelaide.

Posizioni attive di Graeme J. Moyle

Società	Posizione	Inizio
Chelsea & Westminster Hospital	Corporate Officer/Principal	01/01/1994

Tutte le posizioni attive di Graeme J. Moyle

Precedenti posizioni note di Graeme J. Moyle

Società	Posizione	Fine
Tobira Therapeutics, Inc. /Old/ Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Graeme J. Moyle

Formazione di Graeme J. Moyle

University of Adelaide

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Graeme J. Moyle

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Tobira Therapeutics, Inc. /Old/ Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA.	Health Technology
Chelsea & Westminster Hospital